Skip navigation links
3M
Albaraka Turk
Avanti
BASF
BNP Paribas
Bosch
Cargill
Citibank
Coca-Cola
Delivery Hero
DHL
Ericsson
Ford
GE
Huawei
Hyundai
ICBC
Intel
Kuveyt Turk
MAN
MANGO
Microsoft
Nestlé
NGN
Novartis
Pfizer
Pirelli
Schneider Electric
Shell
Siemens
Toyota
UniCredit
Unilever
UPS
This page is print preview page.
Click here to return to the page.
Print page

Novartis 

 

Novartis is a global healthcare company based in Basel, Switzerland, whose mission is to use science-based innovation to address some of society’s most challenging healthcare issues. In 2016, Novartis products reached nearly 1 billion people across more than 180 countries. The Novartis Group operates primarily through three divisions that each have a global scale. These divisions are innovative medicines, eye care (Alcon), and generic medicines (Sandoz).

 

The Novartis Pharmaceuticals portfolio addresses a wide range of therapeutic areas, including cardiovascular-metabolic, ophthalmology, respiratory, neuroscience, immunology, and dermatology. Novartis Oncology is a leader in driving the practice of precision oncology treatment.

 

Sandoz is a global leader in generic pharmaceuticals and biosimilars, pioneering novel approaches to help people around the world access high-quality medicines. Sandoz has a portfolio of more than 1,000 products covering all major therapeutic areas. Alcon provides innovative products that enhance quality of life by helping people worldwide see better. Alcon’s Surgical and Vision Care businesses offer a wide spectrum of eye care products.

 

Novartis has been committed to Turkey for more than 60 years. Today, the Novartis Group has four manufacturing sites in Turkey producing key products as well as several globally-exported products. The Group employs more than 2,300 qualified people and has assumed the leading role in the sector with its understanding of creating a people-oriented company culture and the best working place for its employees.

 

In 2016, Novartis Turkey’s total export was USD 150 million. Over the last decade, its exports have exceeded USD 1.3 billion in total. So far, Novartis has invested over USD 250 million in its manufacturing sites in Turkey, two of which are Novartis Global Production Excellence Centers.

 

The Novartis Group is also the leading pharma company in clinical research in Turkey, accounting for 25 percent of all clinical trial investments by multinational corporations in Turkey. In 2016, the overall clinical trial investments were USD 39.5 million. Since 2009, Novartis Turkey has invested USD 145 million in clinical trials in Turkey, helping make Turkish doctors globally more competitive in research.

 

The long-term goal of Novartis Turkey is to continue growing with Turkey and to assume a pioneering role in further advancing the local pharmaceutical industry with more investment, more R&D, and more output.